

Literaturverzeichnis

1. Hollstein M., Sidransky D., Vogelstein B. und Harris C.C. P53 mutations in human cancers. *Science* 253, 49-53, 1991
1. Greenblatt M.S., Bennett W.P., Hollstein M. und Harris C.C. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. *Cancer Res.* 54, 4855-4878, 1994
1. Levine A.J., Momand J. und Finlay C.A. The p53 tumor suppressor gene. *Nature (London)* 351, 453-456, 1991
1. Lee J.M., Abrahamson J.L., Kandel R., Donehower L.A. und Bernstein A. Susceptibility to radiation-carcinogenesis and accumulation of chromosomal breakage in p53 deficient mice. *Oncogene.* 9, 3731-3736, 1994
1. Jacks T., Remington L., Williams B.O., Schmitt E.M., Halachmi S., Bronson R.T. und Weinberg R.A. Tumor spectrum analysis in p53-mutant mice. *Curr. Biol.* 4, 1-7, 1994
1. Lane D.P. P53, guardian of the genome. *Nature* 358, 15-16, 1992
1. Lowe S.W., Schmitt E.M., Smith S.W., Osborne B.A. und Jacks T. P53 is required for radiation-induced apoptosis in mouse thymocytes. *Nature* 362, 847-849, 1993
1. Jacks T. und Weinberg R.A. Cell-cycle control and its watchman. *Nature* 381, 643-644, 1996
1. Lane D.P. und Crawford L.V. T antigen is bound to a host protein in SV40-transformed cells. *Nature* 278, 261-263, 1979
1. Linzer D.I. und Levine A.J. Characterization of a 54K dalton cellular SV40 tumor antigen present in SV40 transformed cells and uninfected embryonal carcinoma cells. *Cell* 17, 43-52, 1979
1. van Tuinen P., Johnson K.R., Ledbetter S.A., Nussbaum R.L., Rovera G. und Ledbetter D. Localization of myeloperoxidase to the long arm of human chromosome 17: relationship to the 15; 17 translocation of acute promyelocytic leukemia. *Oncogene* 1, 319-322, 1987
1. Dvir A., Peterson S.R., Knuth M.W., Lu H. und Dynan W.S. Ku autoantigen is the regulatory component of a template associated protein kinase that phosphorylates RNA polymerase II. *Proc. Natl. Acad. Sci. USA* 89, 11920-11924, 1992
1. Gottlieb T.M. und Jackson S.P. The DNA-dependent protein kinase: requirement for DNA ends and association with Ku antigen. *Cell* 72, 131-142, 1993
1. Anderson C.W. DNA damage and the DNA-activated protein kinase. *Trends Biochem. Sci.* 18, 433-437, 1993
1. Anderson C.W. und Lees-Miller S.P. The nuclear serine/threonine protein kinase DNA-PK. *Crit. Rev. Eukaryotic Gene Expression* 2, 283-314, 1992
1. Lees-Miller S.P., Sakaguchi K., Ullrich S.J., Appella E. und Anderson C.W. Human DNA-activated protein kinase phosphorylates serines 15 and 37 in the amino-terminal transactivation domain of human p53. *Mol. Cell. Biol.* 12, 5041-5049, 1992
1. Morgan S.E. und Kastan M.B. P53 and ATM: cell cycle, cell death, and cancer. *Adv. Cancer Res.* 71, 1-25, 1997

1. Savitsky K., Bar-Shira A., Gilad S., Rotman G., Ziv Y., Vanagaite L., Tagle D.A., Smith S., Uziel T. und Sfez S. A single ataxia telangiectasia gene with a product similar to PI-3 kinase. *Science* 268, 1749-1753, 1995
1. Morgan S.E., Lovly C., Pandita T.K., Shiloh Y. und Kastan M.B. Fragments of ATM which have dominant-negative or complementing activity. *Mol. Cell Biol.* 17, 2020-2029, 1997
1. Painter R.B. und Young B.R. Radiosensitivity in ataxia-telangiectasia: a new explanation. *Proc. Natl. Acad. Sci. USA* 77, 7315-7317, 1980
1. Hoekstra M.F. Responses to DNA damage and regulation of cell cycle checkpoints by the ATM protein kinase family. *Curr. Opin. Genet. Dev.* 7, 170-175, 1997
1. Bentley N.J., Holtzman D.A., Flaggs G., Keegan K.S., DeMaggio A., Ford J.C., Hoekstra M. und Carr A.M. The *Schizosaccharomyces pombe* rad3 checkpoint gene. *EMBO J.* 15, 6641-1151, 1996
1. Lu X. und Lane D.P. Differential induction of transcriptionally active p53 following UV or ionizing radiation: defects in chromosome instability syndromes. *Cell* 75, 765-778, 1993
1. Bloom D. Congenital telangiectatic erythema resembling lupus erythematosus in dwarfs. *Am. J. Dis. Child.* 88, 754-758, 1954
1. Levine A.J. p53, the cellular gatekeeper for growth and division. Ionizing radiation and cell cycle progression in ataxia telangiectasia. *Cell* 88, 323-331, 1997
1. Graeber T.G., Peterson J.F., Tsai M., Monica K., Fornace A.J.Jr. und Giaccia A.J. Hypoxia induces accumulation of p53 protein, but activation of a G1-phase checkpoint by low-oxygen conditions is independent of p53 status. *Mol. Cell Biol.* 14, 6264-6277, 1994
1. Nakano H., Kurihara K., Okamoto M., Tone S. und Shinohara K. Heat-induced apoptosis and p53 in cultured mammalian cells. *Int. J. Radiat. Biol.* 71, 519-529, 1997
1. Beamish H., Khanna K.K. und Lavin M.F. Ionizing radiation and cell cycle progression in ataxia telangiectasia. *Radiat. Res.* 138, 130-131, 1994
1. Westphal C.H. Cell-cycle signaling: Atm displays its many talents. *Curr. Biol.* 7, 789-792, 1997
1. Jongmans W., Artuso M., Vuillaume M., Bresil H., Jackson S.P. und Hall J. The role of Ataxia telangiectasia and the DNA-dependent protein kinase in the p53-mediated cellular response to ionising radiation. *Oncogene* 13, 1133-1138, 1996
1. Yarnold J. Molecular aspects of cellular responses to radiotherapy. *Radiother. Oncol.* 44, 1-7, 1997
1. Malanga M., Pleschke J.M., Kleczkowska H.E. und Althaus F.R. Poly(ADP-ribose) binds to specific domains of p53 and alters its DNA binding functions. *J. Biol. Chem.* 273, 11839-11843, 1998
1. Tsuzuki T., Izumoto S., Ohnishi T., Hiraga S., Arita N. und Hayakawa T. Neural cell adhesion molecule L1 in gliomas: correlation with TGF-beta and p53. *J. Clin. Pathol.* 51, 13-17, 1998
1. Parada L.F., Land H., Weinberg R.A., Wolf D. und Rotter V. Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation. *Nature* 312, 649-651, 1984
1. Jayaraman L., Murthy K.G., Zhu C., Curran T., Xanthoudakis S. und Prives C. Identification of redox/repair protein Ref-1 as a potent activator of p53. *Genes Dev.* 11, 558-570, 1997

1. Khanna K.K. und Lavin M.F. Ionizing radiation and UV induction of p53 protein by different pathways in ataxia-telangiectasia cells. *Oncogene* 8, 3307-3312, 1993
1. Milne D.M. Campbell L.E., Campbell D.G. und Meek D.W. P53 phosphorylated in vitro and vivo by an ultraviolet radiation-induced protein kinase characteristic of the c-Jun kinase, JNK1. *J. Biol. Chem.* 270, 5511-5518, 1995
1. Kastan M.B., Onyekwere O., Sidransky D., Vogelstein B. und Craig R.W. Participation of p53 protein in the cellular response to DNA damage. *Cancer Res.* 51, 6304-6311, 1991
1. Hain J., Weller E.M., Jung T. und Burkart W. Effects of ionizing- and UV B-radiation on proteins controlling cell cycle progression in human cells: comparison of the MCF-7 adenocarcinoma and the SCL-2 squamous cell carcinoma cell line. *Int. J. Radiat. Biol.* 70, 261-271, 1996
1. Kuerbitz S.J., Plunkett B.S., Walsh W.V. und Kastan M.B. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. *Proc. Natl. Acad. Sci. USA* 89, 7491-7495, 1992
1. Steegenga W.T., van der Eb A.J. und Jochemsen A.G. How phosphorylation regulates the activity of p53. *J. Mol. Biol.* 263, 103-113, 1996
1. Sakaguchi K., Sakamoto H., Lewis M.S., Anderson C.W., Erickson J.W., Appella E. und Xie D. Phosphorylation of serine 392 stabilizes the tetramer formation of tumor suppressor protein p53. *Biochemistry* 36, 10117-10124, 1997
1. Vogelstein B. und Kinzler K.W. p53 function and dysfunction. *Cell* 70, 523-526, 1992
1. Zambetti G.P. und Levine A.J. A comparison of the biological activities of wild-type and mutant p53. *FASEB J.* 7, 855-865, 1993
1. Oliner J.D., Kinzler K.W., Meltzer P.S., George D.L. und Vogelstein B. Amplification of a gene encoding a p53-associated protein in human sarcomas. *Nature* 358, 80-83, 1992
1. Perry M.E., Piette J., Zawadzki J.A., Harvey D. und Levine A.J. The mdm-2 gene is induced in response to UV light in a p53-dependent manner. *Proc. Natl. Acad. Sci. USA* 90, 11623-11627, 1993
1. Oltvai Z.N., Millman C.L. und Korsmeyer S.J. Bcl-2 heterodimerises in vivo with a conserved homolog, BAX, that accelerates programmed cell death. *Cell* 74, 609-619, 1993
1. Kastan M.B., Zhan Q., El-Deiry W. S., Carrier F., Jacks T., Walsh W.V., Plunkett B.S., Vogelstein B. und Fornace A.J. A mammalian cell cycle checkpoint pathway utilizing p53 and GADD45 is defective in ataxia-telangiectasia. *Cell* 71, 587-597, 1992
1. El-Deiry W.S., Tokino T., Velculescu V.E., Levy D.B., Parsons R., Trent J.M., Lin D., Mercer E., Kinzler K.W. und Vogelstein B. WAF-1, a potential mediator of p53 tumor progression. *Cell* 75, 817-825, 1993
1. Fontanini G., Bigini D., Vignati S., Macchiarini P., Pepe S., Angeletti C.A., Pingitore R. und Squartini F. p53 expression in non small cell lung cancer: clinical and biological correlations. *Anticancer Res.* 13, 737-742, 1993
1. Prada L.F., Land H., Weinberg R.A., Wolf D. und Rotter V. Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation. *Nature* 312, 649-651, 1984
1. Todaro G.J. und Green H. Quantitative studies of the growth of mouse embryo cells in culture and their development into established lines. *J. Cell Biol.* 17, 299-313, 1964

1. Hunt T. Maturing promoting factor, cyclin, and the control of M-phase. *Curr. Opin. Cell Biol.* 1, 274-286, 1989
1. Sherr C.J. G1 phase progression: cycling on cue. *Cell* 79, 551-555, 1994
1. Howard A. und Pelc S.R. Synthesis of desoxyribonucleic acid in normal and irradiated cells and its relation to chromosome breakage. *Heredity (London)* 6, 261-273, 1953
1. Lajatha L.G., Oliver R., Berry R. und Noyes W.D. Mechanism of radiation effects on the process of synthesis of desoxyribonucleic acid. *Nature* 182, 1788-1790, 1958
1. Little J.B. Delayed initiation of DNA synthesis in irradiated human diploid cells. *Nature* 218, 1064-1065, 1968
1. Hartwell L.H. und Weinert T.A. Checkpoints: controls that ensure the order of cell cycle events. *Science* 246, 629-634, 1989
1. Harper J.W., Adami G.R., Wei N., Keyomarsi K. und Elledge S.J. The p21 Cdk-interacting protein *cip1* is a potent inhibitor of G1 cyclin-dependent kinases. *Cell* 75, 805-816, 1994
1. Enoch T. und Nurse P. Mutation of fission yeast cell cycle control genes abolishes dependence of mitosis on DNA replication. *Cell* 60, 665-673, 1990
1. Lee J.M. und Bernstein A. p53 mutations increase resistance to ionizing radiation. *Proc. Nat. Acad. Sci. USA* 90, 5742-5746, 1993
1. Zölzer F., Hillebrandt S. und Streffer C. Radiation induced G1-Block and p53 status in six human cell lines. *Radiother. Oncol.* 37, 20-28, 1997
1. Russell K.J., Wiens L.W., Demers G.W., Galloway D.A., Plon S.E. und Groudine M. Abrogation of the G2 checkpoint results in differential radiosensitization of G1 checkpoint-deficient and G1 checkpoint-competent cells. *Cancer Res.* 55, 1639-1642, 1995
1. Bristow R.G., Benchimol S. und Hill R.P. The p53 gene as a modifier of intrinsic radiosensitivity: implications for radiotherapy. *Radiother. Oncol.* 40, 197-223, 1996
1. Howard A. und Pelic S.R. Synthesis of desoxyribonucleic acid in normal and irradiated cells and its relation to chromosome breakage. *Heredity (London)* 6, 261-273, 1953
1. Whitmore G.F., Stanners C.P., Till J.E. und Gulyas S. Nucleic acid synthesis and the division cycle in x-irradiated L-strain mouse cells. *Biochim. Biophys. Acta* 47, 66-77, 1961
1. Terasima T. und Tolmach L.J. Variations in several responses of HeLa cells to X-irradiation during the division cycle. *Biophys. J.* 3, 11-33, 1963
1. Elkind M.M., Han A. und Volz K.W. Radiation response of mammalian cells grown in culture. IV. Dose dependence of division delay and postirradiation growth of surviving and nonsurviving Chinese hamster cells. *J. Natl. Cancer Inst.* 30, 705-721, 1963
1. Molls M. und Streffer C. The influence of G2 progression on X-ray sensitivity of two-cell mouse embryos. *Int. J. Radiat. Biol.* 46, 355-365, 1984
1. Weinert T.A. und Hartwell L.H. The RAD9 gene controls the cell cycle response to DNA damage in *Saccharomyces cerevisiae*. *Science* 241, 317-322, 1988

1. Draetta G. und Beach D. The mammalian cdc2 protein kinase: mechanisms of regulation during the cell cycle. *J. Cell Sci. Suppl.* 12, 21-27, 1989
1. Kharbanda S., Salleem A., Datta R., Yuan Z.M., Weichselbaum R. und Kufe D. Ionizing radiation induces rapid tyrosine phosphorylation of p34cdc2. *Cancer Res.* 54, 1412-1414, 1994
1. Kohn K.W., Jackman J. und O'Connor P.M. Cell cycle control and cancer chemotherapy. *J. Cell. Biochem.* 54, 440-452, 1994
1. Jung T. und Streffer C. Effects of caffeine on protein phosphorylation and cell cycle progression in X-irradiated two-cell mouse embryos. *Int. Radiat. Biol.* 62, 161-168, 1992
1. Busse P.M., Bose S.K., Jones R.W. und Tolmach L.J. The action of caffeine on X-irradiated HeLa cells. III. Enhancement of X-ray-induced killing during G2 arrest. *Radiat. Res.* 76, 292-307, 1978
1. Natarajan A.T., Obe G. und Dulout F.N. The effect of caffeine posttreatment on X-ray-induced chromosomal aberrations in human blood lymphocytes in vitro. *Hum. Genet.* 54, 183-189, 1980
1. Musk S.R. Reduction of radiation-induced cell cycle blocks by caffeine does not necessarily lead to increased cell killing. *Radiat. Res.* 125, 262-266, 1991
1. Powell S.N., DeFrank J.S., Connell P., Eogan M., Preffer F., Dombkowski D., Tang W. und Friend S. Differential sensitivity of p53(-) and p53(+) cells to caffeine-induced radiosensitization and override of G2 delay. *Cancer Res.* 55, 1643-1648, 1995
1. Fornace A.J. Jr., Nebert D.W., Hollander M.C., Luethy J.D., Papathanasiou M., Fargnoli J. und Holbrook N.J. Mammalian genes coordinately regulated by growth arrest signals and DNA-damaging agents. *Mol. Cell. Biol.* 9, 4196-4203, 1989
1. Smith M.L., Chen I.-T., Zhan Q., Bae I., Chen C.-Y., Gilmer T.M., Kastan M.B., O'Connor P.M. und Fornace A.J. Interaction of the p53-regulated protein Gadd45 with proliferating cell nuclear antigen. *Science* 266, 1376-1380, 1994
1. Marx J. New link found between p53 and DNA repair. *Science* 266, 1321-1322, 1994
1. Seroz T., Hwang J.R., Moncollin V. und Egly J.M. FIIH: a link between transcription, DNA repair and cell cycle regulation. *Curr. Opin. Genet. Dev.* 5, 217-221, 1995
1. Payne C.M., Bernstein C. und Bernstein H. Apoptosis overview emphasizing the role of oxidative stress, DNA damage and signal-transduction pathways. *Leuk. Lymphoma* 19, 43-93, 1995
1. Götz C. und Montenarh M. p53: DNA damage, DNA repair, and apoptosis. *Rev. Physiol. Biochem. Pharmacol.* 127, 65-95, 1996
1. Korsmeyer S.J. Regulators of cell death. *Trends Genet.* 11, 101-105, 1995
1. Rao L. und White E. Bcl-2 and ICE family of apoptotic regulators: Making a connection. *Curr. Opin. Genet. Dev.* 7, 52-58, 1997
1. Nigro J.M., Baker S.J., Presinger A.C., Jessup J.M., Hosstetter R., Clearly K., Bigner S.H., Davidson N., Baylin S., Devilee P., Glover T., Collins F.S., Weston A., Modali R., Harris C.C. und Vogelstein B. Mutations in the p53 gene occur in diverse human tumour types. *Nature* 342, 705-708, 1989

1. Bartek J., Bartkova J., Vojtesek B., Staskova Z., Lukas J., Rejthar A., Kovarik J., Midgley C.A., Gannon J.V. und Lane D.P. Aberrant expression of the p53 oncoprotein is a common feature of a wide spectrum of human malignancies. *Oncogene* 6, 1699-1703, 1991
1. Montenarh M. Marker genes for cytotoxic exposure: p53. *Stem Cells (Day)* 1, 136-141, 1995
1. Ueda H., Ullrich S.J., Gangemi J.D., Kappel C.A., Ngo L., Feitelson M.A. und Jay G. Functional inactivation but not structural mutation of p53 causes liver cancer. *Nature Genet.* 9, 41-47, 1995
1. Fearon E.R. und Vogelstein B. A genetic model for colorectal tumorigenesis. *Cell* 61, 759-767, 1990
1. Cavenee W.K., Scrabble H.J. und James C.D. Molecular genetics of human cancer predisposition and progression. *Mutat. Res.* 247, 199-202, 1991
1. Kern S.E., Pietenpol J.A., Thiagalingam S., Seymour A., Kinzler K.W. und Vogelstein B. Oncogenic forms of p53 inhibit p53-regulated gene expression. *Science*, 256, 827-830, 1992
1. Murnane J. Cell cycle regulation in response to DNA damage in mammalian cells: a historical perspective. *Cancer Metastasis Rev.* 14, 17-29, 1995
1. Paules R.S., Levedakou E.N., Wilson S.J., Innes C.L., Rhodes N., Tlsty T.D., Galloway D.A., Donehower L. A., Tainsky M. A. und Kaufmann W.K. Defective G2 checkpoint function in cells from individuals with familial cancer syndromes. *Cancer Res.* 55, 1763-1773, 1995
1. Fukasawa K., Choi T., Kuriyama R., Rulong S. und Vande Woude G.F. Abnormal centrosome amplification in the absence of p53. *Science* 271, 1744-1747, 1996
1. Lundblad V. und Szostak J.W. A mutant with a defect in telomere elongation leads to senescence in yeast. *Cell* 57, 633-643, 1989
1. Hastie N.D., Dempster M., Dunlop M.G., Thompson A.M., Green D.K. und Allshire R.C. Telomere reduction in human colorectal carcinoma and with aging. *Nature* 346, 866-868, 1990
1. Greider C.W. Telomeres, telomerase and senescence. *Bioassays* 12, 363-369, 1990
1. Levy M.Q., Allsopp R.C., Futcher A.B., Greider C.W. und Harley C.B. Telomere end-replication problem and cell aging. *J. Mol. Biol.* 225, 951, 1991
1. Hartwell L.H. und Kastan M.B. Cell cycle control and cancer. *Science* 266, 1821-1828, 1994
1. Pandita T.K., Benvenuto J.A., Shay J.W., Pandita R.K., Rakovitch E., Geard C.R., Antman K.H. und Newman R.A. Effect of penclomedine (NSC-338720) on telomere fusions, chromatin blebbing, and cell viability with and without telomerase activity and abrogated p53 function. *Biochem. Pharmacol.* 53, 409-415, 1997
1. Bond J., Haughton M., Blaydes J., Gire V., Wynford-Thomas D. und Wyllie F. Evidence that transcriptional activation by p53 plays a direct role in the induction of cellular senescence. *Oncogene* 13, 2097-2104, 1996
1. von Zglinicki T. und Saretzki G. Molecular mechanisms of senescence in cell culture. *Z. Gerontol. Geriatr. jan.* 30, 24-28, 1997
1. Vaziri H. und Benchimol S. From telomere loss p53 induction and activation of a DNA-damage pathway at senescence: the telomere loss/DNA damage model of cell aging. *Exp. Gerontol.* 31, 295-301, 1996

1. Pandita T.K., Hall E.J., Hei T.K., Piatyszek M.A., Wright W.E., Piao C.Q., Pandita R.K., Willey J.C., Geard C.R., Kastan M.B. und Shay J.W. Chromosome end-to-end associations and telomerase activity during cancer progression in human cells after treatment with alpha-particles simulating radon progeny. *Oncogene* 13, 1423-1430, 1996
1. Weininger J., Guichard M., Joly A.M., Malaise E.P. und Lachat B. Radiosensitivity and growth parameters in vitro of three human melanoma cell strains. *Int. J. Radiat. Biol.* 34, 285-290, 1978
1. Nagasawa H., Robertson J.B., Arundel C.S. und Little J.B. The effect of X irradiation on the progression of mouse 10T1/2 cells released from density-inhibited cultures. *Radiat. Res.* 97, 537-545, 1984
1. Dolbeare F., Gratzner H., Pallavicini M.G. and Gray J.W. Flow cytometric measurements of total DNA content and incorporated bromodeoxyuridine. *Proc. Natl. Acad. Sci. USA* 80, 5573-5577, 1983
1. Remvikos Y., Laurent-Puig P., Salmon R.J., Frelat G., Dutrillaux B. und Thomas G. Simultaneous monitoring of p53 protein and DNA content of colorectal adenocarcinomas by flow cytometry. *Int. J. Cancer* 45, 450-456, 1990
1. Laemmli U.K., Molbert E., Showe M. und Kellenberger E. Form-determining function of the genes required for the assembly of the head of bacteriophage T4. *J. Mol. Biol.* 49, 99-113, 1970
1. Levine A.J. Tumor suppressor genes. *Bioassays* 12, 60-66, 1990
1. Darzynkiewicz Z., Staiano-Coico L., Kunicka J.E., Deleo A.B. und Old L.J. P53 content in relation to cell growth and proliferation in murine L1210 leukemia and normal lymphocytes. *Leukemia Res.* 10, 1383-1389, 1986
1. Laffin J., Fogleman D. und Lehman J.M. Correlation of DNA content, p53, T antigen, and V antigen in simian virus 40-infected human diploid cells. *Cytometry* 10, 205-213, 1989
1. Lanza F., Bi S. und Goldmann J.M. Similarity of p53 expression by cd34+ cells in chronic myeloid leukemia and normal progenitors detected by flow cytometry. *Blood* 80, 1857-1858, 1992
1. Brotherick I., Shenton B.K., Cowan W.K., Angus B., Horne C.H.W., Higgs J.M. und Lennard T.W.J. P53 expression measured by flow cytometry. *Cancer Immunol. Immunother.* 41, 146-150, 1995
1. Morkve O., Halvorsen O.J., Stangeland L., Gulsvik A. und Laerum O.D. Quantitation of biological tumor markers (p53, c-myc, Ki-67 and DNA ploidy) by multiparameter flow cytometry in non-small-cell lung cancer. *Int. J. Cancer* 52, 851-855, 1992
1. Milner J. und Milner S. SV40-53k antigen: a possible role for 53k in normal cells. *Virology* 112, 785, 1981
1. Shen D.W., Real F.X., DeLeo A.B., Old J.L. und Baserga R. Protein p53 and inducer-mediated erythroleukemia cell commitment to terminal cell division. *Proc. Natl. Acad. Sci. U.S.A.* 80, 5919-5922, 1983
1. Shaulsky G., Goldfinger N., Tosky M.S., Levine A.J. und Rotter V. Nuclear localization is essential for the activity of p53-Protein. *Oncogene* 6, 2055-2065, 1991
1. Ramel S., Reid B.J., Sanchez R.C., Blount P.L., Levine D.S., Neshat K., Haggitt R.C., Dean P.J., Thor K. und Rabinovitch S. Evaluation of p53-Protein expression in barretts's esophagus by two-parameter flow cytometry. *Gastroenterology* 102, 1220-1228, 1992

1. Varelly J.M., Brammar W.J., Lane D.P., Swallow J.E., Dolan C. und Walker R.A. Loss of chromosome 17p13 sequences and mutation of p53 in human breast carcinomas. *Oncogene* 6, 413-421, 1991
1. Ginsberg D., Michael-Michalovitz D. und Oren M. Induction of growth arrest by a temperature-sensitive p53 mutant is correlated with increased nuclear localization and decreased stability of the protein. *Mol. Cell. Biol.* 11, 582-585, 1991
1. Gannon J.V. und Lane D.P. Protein synthesis required to anchor a mutant p53 protein which is temperature-sensitive for nuclear transport. *Nature (Lond.)* 349, 802-805, 1991
1. Blagosklonny M.V. Loss of function and p53-Protein stabilization. *Oncogene* 15, 1889-1893, 1997
1. Cornelis R.S., van Vliet M., Vos C.J.B., Cleton-Janseb A.M., van de Vijer M.J., Peterse J.L., Meera Kahn P., Borresen A.-L. und Cornelisse C.J. Evidence for a gene on 17p13.3 distal to TP53, as a target for allele loss in breast tumors without p53 mutations. *Cancer Res.* 54, 4200-4206, 1994
1. Deng G., Chen L.C., Schott D.R., Thor A., Bhargava V., Ljung B.M., Chew K. und Smith H.S. Loss of heterozygosity and p53 gene mutations in breast cancer. *Cancer Res.* 54, 499-505, 1994
1. Daniels D.A. und Lane D.P. The characterisation of p53 binding phage isolated from phage peptide display libraries. *J. Mol. Biol.* 243, 4, 639-652, 1994
1. Waterman M.J. Waterman J.L. und Halazonetis T.D. An engineered four-stranded coiled coil substitutes for the tetramerization domain of wild-type p53 and alleviates transdominant inhibition by tumor-derived p53 mutants. *Cancer Res.* 56, 158-163, 1996
1. Rolley N., Butcher S. und Milner J. Specific DNA binding by different classes of human p53 mutants. *Oncogene* 11, 763-770, 1995
1. Delmolino L., Band H. und Band V. Expression and stability of p53 protein in normal human mammary epithelial cells. *Carcinogenesis* 14, 827-832, 1993
1. Vojtesek B. und Lane D.P. Regulation of p53 protein expression in human breast cancer cell lines. *J. Cell. Sci.* 105, 607-612, 1993
1. Fritsche M., Haessler C. und Brandner G. Induktion of nuclear accumulation of the tumor-suppressor protein p53 by DNA-damaging agents. *Oncogene* 8, 307-318, 1993
1. Cooper K., Herrington C.S., Evans M.F., Gatter K.C. und McGee J.O. P53 antigen in cervical condylomata, intraepithelial neoplasia, and carcinoma: relationship to HPV infection and integration. *J. Pathol.* 171, 27-34, 1993
1. Zölzer F. Störungen der Zellproliferation und ihre Bedeutung für prädiktive Tests in der Tumortherapie mit ionisierenden Strahlen. Habilitationsschrift im Fach Strahlenbiologie am Universitätsklinikum Essen
1. Maltzman W. und Czyzyk L. UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells. *Mol. Cell. Biol.* 4, 1689-1694, 1982
1. Lu X. und Lane D.P. Differential induction of transcriptionally active p53 following uv or ionizing radiation. *Cell* 75, 765-778, 1993
1. Meyn R.E., Stephens L.C., Voehringer D.W., Story M.D., Mirkovic N. und Milas L. Biochemical modulation of radiation-induced apoptosis in murine lymphoma cells. *Radiat. Res.* 136, 327-334, 1993

1. Falkvoll K.H. The occurrence of apoptosis, abnormal mitoses, cells dying in mitosis and micronuclei in human melanoma xenograft exposed to single dose irradiation. *Strahlenther. Onkol.* 166, 487-492, 1990
1. Yamada T. und Ohyama H. Radiation-induced interphase death of rat thymocytes is internally programmed (apoptosis). *Int. J. Radiat. Biol.* 53, 65-75, 1988
1. Payne C.M., Bjore C.G. und Schultz D.A. Change in the frequency of apoptosis after low- and high-dose X-irradiation of human. *J. Leukoc. Biol.* 52, 433-440, 1992
1. Gotz C. und Montenarh M. P53 and its implications in apoptosis. *Int. J. Oncol.* 6, 1129-1135, 1995
1. Wilson J.W., Pritchard D.M., Hickman J.A. und Potten C.S. Radiation-induced p53 and p21WAF-1/CIP1 expression in the murine intestinal epithelium: apoptosis and cell cycle arrest. *Am. J. Pathol.* 153, 899-909, 1998
1. Lin Y. und Benchimol S. Cytokines inhibit p53-mediated apoptosis but not p53-mediated G1 arrest. *Mol. Cell Biol.* 15, 6045-6954, 1995
1. Dee S., Haas-Kogan D.A. und Israel M.A. Inactivation of p53 associated with decreased levels of radiation -induced apoptosis in medulloblastoma cell lines. *Cell Death Different.* 2, 267-75, 1995
1. Haas-Kogan D.A., Yount G., Haas M., Levi D., Kogan S.S., Hu L., Vidair C., Deen D.F., Dewey W.C. und Israel M.A. P53-dependent G1 arrest and p53-independent apoptosis influence the radiobiologic response of glioblastoma. *Int. J. Radiat. Oncol. Biol. Phys.* 36, 95-103, 1996
1. Rubin L.L., Philpott K.L. und Brooks S.F. The cell cycle and cell death. *Curr. Biol.* 3, 391-394, 1993
1. Abend M. und van Beuningen D. Bedeutung apoptotischer Prozesse für die Strahlentherapie. *Strahlenther. Onkol.* 174, 212-216, 1998
1. Benchimol S., Pim D. und Crawford L. Radioimmunoassay of the cellular protein p53 in mouse and human cell lines. *The EMBO Journal* 1, 1055-1062, 1982
1. Oren M., Maltzman W. und Levine A.J. Post-translational regulation of the 54K cellular tumor antigen in normal and transformed cells. *Mol. Cell Biol.* 1, 101-110, 1981
1. Sarnow P., Ho Y.S., Williams J. und Levine A.J. Adenovirus E1b-58kd tumor antigen and SV40 large tumor antigen are physically associated with the same 54 kd cellular protein in transformed cells. *Cell* 28, 387-394, 1982
1. Laffin J., Fogleman D. und Lehman J.M. Correlation of DNA content, p53, T antigen, and V antigen in simian virus 40-infected human diploid cells. *Cytometry* 10, 205-213, 1989
1. Halevy O., Hall A. und Oren M. Stabilization of the p53 transformation-related protein in mouse fibrosarcoma cell lines: effects of protein sequence and intracellular environment. *Mol. Cell Biol.* 9, 3385-3392, 1989
1. Deppert W. und Steinmayer T. Metabolic stabilization of p53 in SV40-transformed cells correlates with expression of the transformed phenotype but is independent from complex formation with SV40 large T antigen. *Curr. Top. Microbiol. Immunol.* 144, 77-83, 1989
1. Agrawal R.S., Agrawal Y.P. und Mäntyjärvi R.A. Flow cytometric quantitation of c-myc and p53-Proteins in bovine papilloma type 1-transformed primary mouse fibroblasts. *Cytometry* 17, 237-245, 1994

1. Deppert W. und Haug M. Evidence for free and metabolically stable p53-Protein in nuclear subfractions of simian virus 40-transformed cells. *Mol. Cell Biol.* 6, 2233-2240, 1986
1. Deppert W., Steinmayer T. und Richter W. Cooperation of SV40 large T antigen and the cellular protein p53 in maintenance of cell transformation. *Oncogene* 4, 1103-1110, 1989
1. Gannon J.V., Greaves R., Iggo R. und Lane D.P. Activating mutations in p53 produce a common conformational effect. A monoclonal antibody specific for the mutant form. *The EMBO J.* 9, 1595-1602, 1990
1. Lane D.P. und Benchimol S. p53: oncogene or anti-oncogene?. *Genes Dev.* 4, 1-8, 1990
1. Schmieg F.I. und Simmons D.T. P53 mutants with changes in conserved region II: three classes with differing antibody reactivity, SV40 T antigen binding and ability to inhibit transformation of rat cells. *Oncogene* 8, 2043-2050, 1993
1. Montenarh M., Kohler M. und Henning R. Complex formation of simian virus 40 large T antigen cellular protein p53. *J. Virol.* 60, 761-764, 1986
1. Kuhar S. G. und Lehman J. M. T antigen and p53 in pre- and post-crisis simian virus 40-transformed human cell lines. *Oncogene* 9, 1499-506, 1991
1. Lehman J.M., Perry Albano M.B. und Laffin J. Induction of tetraploid dna content by mutant simian virus 40 T antigen that has reduced complex formation with p53. *Cytometry* 23, 126-130, 1996
1. Ozer H.L., Banga S.S., Dasgupta T., Houghton J., Hubbard K., Jha K.K., Kim S.H., Lenahan M., Pang Z., Pardinis J.R. und Patsalis P.C. SV-40-mediated immortalization of human fibroblasts. *Exp. Gerontol.* 31, 303-310, 1996
1. Elledge R.M., Clark G.M., Fuqua S.A.W., Yu Yi-Yang und Allred D.C. P53-Protein accumulation detected by five different antibodies: relationship to prognosis and heat shock protein 70 in breast cancer. *Cancer Res.* 54, 3752-3757, 1994
1. Jacquemier J., Moles J.P., Penault-Llorca F., Adelaide J., Torrente M., Viens P., Birnbaum D. und Theillet C. P53 immunohistochemical analysis in breast cancer with four monoclonal antibodies: comparison of staining and PCR-SSCP results. *Brit. J. Cancer* 69, 846-852, 1994
1. Haapajärvi T., Kivinen L., Pitkänen K. und Laiho M. Cell cycle dependent effects of u.v.-radiation on p53 expression and retinoblastoma protein phosphorylation. *Oncogene* 1, 151-159, 1995
1. Rivas C.I., Wisniewski D., Strife A., Perez A., Lambek C., Bruno S., Darzynkiewicz Z. und Clarkson B. Constitutive expression of p53 protein enriched normal human marrow blast cell populations. *Blood* 79, 1982-1986, 1992
1. Milner J. The role of p53 in the normal control of cell proliferation. *Current Opinion in Cell Biology* 3, 282-286, 1991
1. Long S.B., Ho H.Y., Chen C.L. und Lai M.D. Complex of simian virus large T antigen and p53 can bind DNA specifically. *Anticancer Res.* 15, 1375-1380, 1995
1. Hess R.D. und Brandner G. DNA-damage-inducible p53 activity in SV40-transformed cells. *Oncogene* 15, 2501-2504, 1997

1. Gorman S.D. und Cristofalo V.J. Analysis of the G1 arrest position of senescent WI38 cells by quinacrine dihydrochloride nuclear fluorescence. Evidence for a late G1 arrest. *Exp. Cell. Res.* 167, 87-94, 1986

1. Kitagawa M., Higashi H., Takahashi I.S., Okabe T., Ogino H., Taya Y., Hishimura S. und Okuyama A. A cyclin-dependent kinase inhibitor, butyrolactone 1, inhibits phosphorylation of RB protein and cell cycle progression. *Oncogene* 9, 2549-2557, 1994

1. Coppock D.L., Kopman C., Scandalis S. und Gilleran S. Preferential gene expression in quiescent human lung fibroblasts. *Cell Growth Differ.* 4, 483-493, 1993

1. Yamagishi N., Miyakoshi J., Ohtsu S., Day R.S. 3rd und Takebe H.J. Modification of radiosensitivity of human cells to which simian virus 40 T-antigen was transfected. *J. Radiat. Res. (Tokyo)* 36, 239-247, 1995